Schwab Charles Investment Management Inc. boosted its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 5.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 198,419 shares of the medical research company’s stock after buying an additional 11,115 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.25% of NeoGenomics worth $1,566,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in shares of NeoGenomics by 7.1% in the first quarter. Vanguard Group Inc. now owns 2,679,783 shares of the medical research company’s stock worth $21,144,000 after buying an additional 176,691 shares during the period. Emerald Advisers Inc. PA boosted its stake in shares of NeoGenomics by 30.5% in the first quarter. Emerald Advisers Inc. PA now owns 1,274,860 shares of the medical research company’s stock worth $10,059,000 after buying an additional 297,604 shares during the period. Cowen Prime Services LLC boosted its stake in shares of NeoGenomics by 23.4% in the first quarter. Cowen Prime Services LLC now owns 1,188,476 shares of the medical research company’s stock worth $9,377,000 after buying an additional 225,550 shares during the period. Uniplan Investment Counsel Inc. boosted its stake in shares of NeoGenomics by 5.2% in the first quarter. Uniplan Investment Counsel Inc. now owns 909,528 shares of the medical research company’s stock worth $7,176,000 after buying an additional 45,265 shares during the period. Finally, Emerald Mutual Fund Advisers Trust boosted its stake in shares of NeoGenomics by 16.2% in the first quarter. Emerald Mutual Fund Advisers Trust now owns 907,529 shares of the medical research company’s stock worth $7,160,000 after buying an additional 126,851 shares during the period. Institutional investors own 82.56% of the company’s stock.

Shares of NeoGenomics, Inc. (NEO) traded down 2.63% during mid-day trading on Friday, reaching $9.24. The company had a trading volume of 207,022 shares. NeoGenomics, Inc. has a one year low of $6.90 and a one year high of $9.93. The stock’s market capitalization is $733.55 million. The firm has a 50 day moving average of $9.26 and a 200-day moving average of $8.30.

NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings data on Tuesday, July 25th. The medical research company reported $0.04 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.01 by $0.03. NeoGenomics had a positive return on equity of 6.09% and a negative net margin of 2.81%. The company had revenue of $66.09 million for the quarter, compared to analysts’ expectations of $62.95 million. During the same period in the previous year, the firm posted $0.04 EPS. NeoGenomics’s revenue was up 4.7% compared to the same quarter last year. Analysts forecast that NeoGenomics, Inc. will post $0.18 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Schwab Charles Investment Management Inc. Increases Stake in NeoGenomics, Inc. (NEO)” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/27/schwab-charles-investment-management-inc-increases-stake-in-neogenomics-inc-neo.html.

A number of analysts recently issued reports on the company. BidaskClub raised NeoGenomics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, July 19th. Zacks Investment Research raised NeoGenomics from a “sell” rating to a “hold” rating in a report on Saturday, July 29th. ValuEngine raised NeoGenomics from a “sell” rating to a “hold” rating in a report on Friday, June 23rd. BTIG Research reissued a “buy” rating and set a $11.00 price objective on shares of NeoGenomics in a report on Sunday, May 28th. Finally, Cantor Fitzgerald set a $11.00 price objective on NeoGenomics and gave the stock a “buy” rating in a report on Saturday, May 27th. One analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. NeoGenomics has an average rating of “Buy” and a consensus target price of $10.17.

In other NeoGenomics news, insider Steven A. Ross sold 70,833 shares of the firm’s stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $7.76, for a total value of $549,664.08. Following the transaction, the insider now directly owns 4,500 shares of the company’s stock, valued at approximately $34,920. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Jennifer Balliet sold 10,723 shares of the firm’s stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $8.49, for a total transaction of $91,038.27. The disclosure for this sale can be found here. Insiders own 12.20% of the company’s stock.

About NeoGenomics

NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.

Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Stock Ratings for NeoGenomics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics Inc. and related stocks with our FREE daily email newsletter.